Preparation and characterization of monomethoxy poly(ethylene glycol)-poly(&amp;epsilon;-caprolactone) micelles for the solubilization and in vivo delivery of luteolin

Qiu, Jinfeng; Gao, Xiang; Wang, Bilan; Wei, Xiawei; Gou, Maling; Men, Ke; Liu, Xingyu; Guo, Gang; Qian, Zhiyong; Huang, Meijuan

doi:10.2147/ijn.s45062

Cited by 20 publications

(9 citation statements)

References 33 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another researcher also found similar results regarding zeta potential [37]. A negative zeta potential avoids the aggregation of nanoformulations and stabilizes them against electrostatic interaction forces.…”

Section: Particle Size and Zeta Potentialsupporting

confidence: 54%

“…The MPEG-PCL micelles showed a negative zeta potential based on the surface charge on polymeric micelles, for which there could be many reasons such as the chemical structure of the MPEG-PCL polymer, the pH of the diluting medium, and the ionic strength of the medium. Another researcher also found similar results regarding zeta potential [37]. A negative zeta potential avoids the aggregation of nanoformulations and stabilizes them against electrostatic interaction forces.…”

Section: Particle Size and Zeta Potentialsupporting

confidence: 54%

See 1 more Smart Citation

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

et al. 2020

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) will be responsible for the vision impairment of more than five million late-aged adults in the next 30 years. Current treatment includes frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. However, there are methods of drug delivery that can decrease the frequency of intravitreal injections by sustaining drug release. MPEG-PCL ((methoxypoly(ethylene glycol) poly(caprolactone)) has been reported as biocompatible and biodegradable. Polymeric micelles of MPEG-PCL can be useful in efficiently delivering anti-VEGF drugs such as sunitinib to the posterior segment of the eye. In this study, the novel micellar formulation exhibited an average dynamic light scattering (DLS) particle size of 134.2 ± 2.3 nm with a zeta potential of −0.159 ± 0.07 mV. TEM imaging further confirmed the nanoscopic size of the micelles. A sunitinib malate (SM)-MPEG-PCL formulation exhibited a sustained release profile for up to seven days with an overall release percentage of 95.56 ± 2.7%. In addition to their miniscule size, the SM-MPEG-PCL formulation showed minimal cytotoxicity onto the ARPE-19 human retinal pigment epithelial cell line, reporting a percent viability of more than 88% for all concentrations tested at time intervals of 24 h. The SM-MPEG-PCL micelles also exhibited exceptional performance during an anti-VEGF ELISA that decreased the overall VEGF protein expression in the cells across a 24–72 h period. Furthermore, it can be concluded that this type of polymeric vehicle is a promising solution to symptoms caused by AMD and improving the management of those suffering from AMD.

show abstract

Section: Particle Size and Zeta Potentialsupporting

confidence: 54%

Section: Particle Size and Zeta Potentialsupporting

confidence: 54%

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

et al. 2020

View full text Add to dashboard Cite

show abstract

“…When temperature increased to near the glass transition temperature, it changed from semi-crystalline to amorphous state, and the activity capacity of polymer chains increased, which allowed amphiphilicity triggered MPEG-PCL micellization and encapsulated the hydrophobic drug (Gou et al., 2009 ). Owing to the amphiphilicity of MPEG-PCL copolymer, the hydrophobic PCL chains formed a ‘core’ to encapsulate insoluble DHA, and the hydrophilic PEG chains formed a ‘shell’ to provide excellent water dispersity (Gou et al., 2011 ; Qiu et al., 2013 ).…”

Section: Discussionmentioning

confidence: 99%

Self-assembled dihydroartemisinin nanoparticles as a platform for cervical cancer chemotherapy

et al. 2020

View full text Add to dashboard Cite

Dihydroartemisinin (DHA) is a potent anti-cancer drug that has limited clinical applications due to poor water solubility and low bioavailability. We designed a biodegradable poly(ethylene glycol) methyl ether-poly(ε-caprolactone) (MPEG-PCL) micelle carrier for DHA using the self-assembly method. The DHA/MPEG-PCL nanoparticles were spherical with an average particle size of 30.28 ± 0.27 nm, and released the drug in a sustained manner in aqueous solution. The drug-loaded nanoparticles showed dose-dependent toxicity in HeLa cells by inducing cycle arrest and apoptosis. Furthermore, compared to free DHA, the DHA/MPEG-PCL nanoparticles showed higher therapeutic efficacy and lower toxicity in vivo , and significantly inhibited tumor growth and prolonged the survival of tumor-bearing nude mice. In addition, the tumor tissues of the DHA/MPEG-PCL-treated mice showed a marked decline in the in situ expression of proliferation and angiogenesis markers. Taken together, the self-assembled DHA/MPEG-PCL nanoparticles are a highly promising delivery system for targeted cancer treatment.

show abstract

“…They studied the pharmacokinetics of free luteolin and the luteolin MPEG-PCL micelles in rats, the results indicating a higher bioavailable concentration of luteolin for the luteolin MPEG-PCL micelles. The in vitro cytotoxicity studies reflected a lower IC 50 for the MPEG-PCL luteolin micelles suggesting that encapsulation of luteolin into MPEG-PCL micelles can potentially enhance the bioavailability and cytotoxicity (Qiu et al, 2013). …”

Section: Micellesmentioning

confidence: 99%

PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs

2018

View full text Add to dashboard Cite

Natural resources continue to be an invaluable source of new, novel chemical entities of therapeutic utility due to the vast structural diversity observed in them. The quest for new and better drugs has witnessed an upsurge in exploring and harnessing nature especially for discovery of antimicrobial, antidiabetic, and anticancer agents. Nature has historically provide us with potent anticancer agents which include vinca alkaloids [vincristine (VCR), vinblastine, vindesine, vinorelbine], taxanes [paclitaxel (PTX), docetaxel], podophyllotoxin and its derivatives [etoposide (ETP), teniposide], camptothecin (CPT) and its derivatives (topotecan, irinotecan), anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin), and others. In fact, half of all the anti-cancer drugs approved internationally are either natural products or their derivatives and were developed on the basis of knowledge gained from small molecules or macromolecules that exist in nature. Three new anti-cancer drugs introduced in 2007, viz. trabectedin, epothilone derivative ixabepilone, and temsirolimus were obtained from microbial sources. Selective drug targeting is the need of the current therapeutic regimens for increased activity on cancer cells and reduced toxicity to normal cells. Nanotechnology driven modified drugs and drug delivery systems are being developed and introduced in the market for better cancer treatment and management with good results. The use of nanoparticulate drug carriers can resolve many challenges in drug delivery to the cancer cells that includes: improving drug solubility and stability, extending drug half-lives in the blood, reducing adverse effects in non-target organs, and concentrating drugs at the disease site. This review discusses the scientific ventures and explorations involving application of nanotechnology to some selected plant derived molecules. It presents a comprehensive review of formulation strategies of phytoconstituents in development of novel delivery systems like liposomes, functionalized nanoparticles (NPs), application of polymer conjugates, as illustrated in the graphical abstract along with their advantages over conventional drug delivery systems supported by enhanced biological activity in in vitro and in vivo anticancer assays.

show abstract

Preparation and characterization of monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) micelles for the solubilization and in vivo delivery of luteolin

Cited by 20 publications

References 33 publications

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

Sunitinib-Loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration

Self-assembled dihydroartemisinin nanoparticles as a platform for cervical cancer chemotherapy

PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs

Contact Info

Product

Resources

About